These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 20354800)

  • 1. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature.
    Cao XL; Li H; Yu XL; Liang P; Dong BW; Fan J; Li M; Liu FY
    PLoS One; 2013; 8(12):e82448. PubMed ID: 24349287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
    Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
    J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis.
    Ward DG; Cheng Y; N'Kontchou G; Thar TT; Barget N; Wei W; Billingham LJ; Martin A; Beaugrand M; Johnson PJ
    Br J Cancer; 2006 Jan; 94(2):287-92. PubMed ID: 16404431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
    Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
    Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.
    Wang N; Cao Y; Song W; He K; Li T; Wang J; Xu B; Si HY; Hu CJ; Li AL
    J Gastroenterol Hepatol; 2014; 29(7):1544-50. PubMed ID: 24612022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.
    Kanmura S; Uto H; Kusumoto K; Ishida Y; Hasuike S; Nagata K; Hayashi K; Ido A; Stuver SO; Tsubouchi H
    Hepatology; 2007 Apr; 45(4):948-56. PubMed ID: 17393466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma.
    Li X; Li B; Li B; Guo T; Sun Z; Li X; Chen L; Chen W; Chen P; Mao Y; Zeng Y
    Pathol Oncol Res; 2018 Jul; 24(3):663-670. PubMed ID: 28828637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
    Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
    PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.
    He QY; Zhu R; Lei T; Ng MY; Luk JM; Sham P; Lau GK; Chiu JF
    J Cell Biochem; 2008 Feb; 103(3):740-52. PubMed ID: 17557278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Jirun P; Zhang G; Kim HK; Ha SA; Zhongtian J; Shishi Q; Zhuqingqing C; Lei G; Yoo J; Kim S; Park YG; Wang J; Yang Y; Xu Z; Huang Z; Lee YK; Song EY; Kim JW
    Dis Markers; 2011; 30(6):307-15. PubMed ID: 21725159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage.
    Lin L; Lu B; Yu J; Liu W; Zhou A
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):397-404. PubMed ID: 26724963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.